AI Letterhead - Issue #6

This week in the AI Letterhead newsletter

The courtroom spotlight is on one of the fastest-growing mass torts in modern pharmaceutical history: the Ozempic litigation. With nearly 2,000 lawsuits now consolidated in federal multidistrict litigation, manufacturers of GLP-1 receptor agonists like Ozempic and Mounjaro face allegations of failing to warn patients about serious side effects such as stomach paralysis, intestinal blockages, and irreversible vision loss. What began as a diabetes drug and off-label weight loss solution is now at the center of a legal reckoning that could redefine how pharmaceutical risks are disclosed, especially when real-world use outpaces clinical trials. This week, we explore this litigation's far-reaching legal, medical, and commercial consequences and what it means for patient safety, regulatory oversight, and pharmaceutical accountability. Also in this issue: we examine how AI is quietly transforming law firm profitability by reclaiming hours once lost to routine tasks, and how agentic AI—goal-directed, decision-making systems—are emerging as powerful tools for client intake and internal operations. We break down a key Ontario Court of Appeal ruling on insurer cost disputes, spotlight procedural and privilege rulings in a legal fee conflict in Elkin Injury Law v. Smith, and share thought leadership on the future of legal practice in an AI-powered world, where lawyers may soon evolve into strategic “AI whisperers.” From mass torts to machine intelligence, this edition connects today's pressing legal challenges with tomorrow's transformative AI tools.

💡 Deep Dive Analysis

Topic: Ozempic Lawsuit

What Happened: The Rapidly Expanding GLP-1 RA Litigation

The pharmaceutical landscape is witnessing one of the fastest-growing mass torts in recent history, with over 1,800 lawsuits consolidated in federal multidistrict litigation (MDL No. 3094) against manufacturers of GLP-1 receptor agonist medications, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro. These lawsuits primarily allege that manufacturers failed to adequately warn patients about serious side effects, including gastroparesis (stomach paralysis), intestinal blockages, vision loss, and other severe complications that weren't disclosed on warning labels when many patients began taking these medications.

Originally prescribed for type 2 diabetes but widely used off-label for weight loss, Ozempic (semaglutide) has become a household name. However, its popularity has coincided with mounting reports of unexpected side effects requiring hospitalization and, in some cases, surgery. The litigation has rapidly expanded from the first lawsuits filed in August 2023 to nearly 2,000 pending actions by May 2025.

Why It Matters: Far-Reaching Legal and Healthcare Implications

This litigation carries significant implications across multiple domains:

For Pharmaceutical Accountability

The ongoing multidistrict litigation (MDL) addresses critical concerns surrounding the obligations of pharmaceutical manufacturers in disclosing risks associated with their products, both for on-label and off-label use. This litigation has the potential to set significant precedents regarding the requirements imposed on manufacturers regarding the timely updating of warning labels in response to post-marketing evidence. Specifically, it seeks to clarify the circumstances under which a drug, once utilized beyond its FDA-approved indications, mandates an adjustment of its warning labels to reflect emerging safety data. The outcome of this litigation may shape industry standards and practices, thereby influencing the safety protocols that govern pharmaceutical communications with healthcare providers and patients alike.

For Patient Safety

The case highlights the tension between the rapid adoption of promising medications and comprehensive safety evaluation. Many side effects allegedly associated with GLP-1 RAs, such as vision loss (NAION) and stomach paralysis, only became apparent after widespread use and weren't captured in the initial clinical trials, which typically lasted less than a year. The litigation may prompt reforms in how drug safety is monitored post-approval.

For Medical Practice

With millions of prescriptions written for these medications, healthcare providers are caught in the middle—balancing the benefits of effective weight management and diabetes control against emerging safety concerns. The litigation could reshape prescribing practices, informed consent protocols, and pre-surgical screening for patients on these medications.

For Economic Impact

Novo Nordisk and Eli Lilly have built multi-billion dollar franchises around these medications. The litigation creates significant uncertainty for shareholders, future product development, and pricing strategies in this highly profitable therapeutic area. Recent Senate hearings on pricing practices add another layer of complexity to the companies' legal challenges.

Beyond the Headlines:

The Ozempic litigation represents more than just another pharmaceutical mass tort—it's a case study of how our legal and regulatory systems handle innovations that provide remarkable benefits and significant risks.

The exclusion of deep vein thrombosis (DVT) and blood clot cases from the MDL is particularly noteworthy, as it creates parallel litigation tracks and suggests these injuries may have different causation profiles than the gastrointestinal complications at the center of the MDL.

Including vision loss claims based on recent studies linking semaglutide to NAION ("eye rotting") could dramatically expand the scope of potential plaintiffs. While gastroparesis and intestinal issues have dominated the narrative so far, irreversible vision damage could potentially eclipse these injuries in terms of both plaintiff numbers and settlement values.

As this litigation progresses, key questions remain:

 Will the emergence of new studies showing increased risks of previously undisclosed side effects strengthen plaintiffs' failure-to-warn claims?

How will courts handle the distinction between those who took these medications for their FDA-approved purpose (diabetes) versus those who took them off-label for weight loss?

How might this litigation influence FDA oversight of the rapidly expanding GLP-1 RA drug class, including newer entrants to the market?

The Ozempic litigation stands at the intersection of pharmaceutical innovation, regulatory oversight, off-label prescribing practices, and evolving standards for patient safety—making it one of the most consequential pharmaceutical legal battles of the decade, regardless of its ultimate outcome.

This analysis captures the key aspects of the Ozempic litigation based on the information in the document. The situation is still evolving, with new cases being added to the MDL regularly and additional studies emerging about potential side effects.

The document shows this is one of the fastest-growing pharmaceutical litigations in recent years. Claims centred around failure to warn about serious side effects not initially disclosed on warning labels. These include gastroparesis (stomach paralysis), intestinal blockages, vision loss issues (NAION), and, in some cases, blood clots.

📈 Quick Bytes

💵 AI Raises Potential to Increase Law Firm Profitability – Study:

A LexisNexis and Forrester Consulting study shows AI boosts law firm profitability by reducing unbillable hours. Partners can reclaim up to 2.5 hours weekly, junior associates recover 35% of their annual hours, and research staff save 225 hours per year. Automating routine tasks allows lawyers to focus on billable work, potentially increasing revenue, provided there are enough new cases. AI challenges the traditional billing model, suggesting efficiency and profitability can coexist. As AI adoption grows, the legal industry must rethink value measurement.  

🧾 ILTA Evolve: Finding the use cases for law firms around agentic AI systems:

Law firms are beginning to explore agentic AI systems, which operate independently to complete tasks without human input. Unlike generative AI, which creates content, agentic AI is goal-oriented and capable of making decisions independently. Legal professionals view it as an efficient assistant rather than a replacement for lawyers. Its applications include marketing, client intake, task recommendations, and voice assistance, helping firms reduce non-billable hours and streamline operations. However, firms must carefully evaluate security, accuracy, ethics, and compliance issues, ensuring that AI complements legal professionals instead of replacing them. As the legal industry embraces the strategic implementation of AI, it remains crucial to maintain a balance between innovation and oversight.

✒️Ont. CA upholds denial of insurer's expense reimbursement claim in motor vehicle accident case:

The Ontario Court of Appeal ruled that a higher-priority insurer is not required to reimburse a lower-priority insurer for pre-arbitration expenses in a priority dispute over Statutory Accident Benefits (SABs). In Echelon General Insurance Company v. Unifund Assurance, an arbitrator initially ordered Unifund to reimburse Echelon for SABs payments and arbitration costs. Still, Echelon sought an additional $100,000 for mediation, adjusting, and legal fees. While the Ontario Superior Court ruled in favor of Echelon, citing the doctrine of unjust enrichment, the Court of Appeal overturned the decision, stating that expense reimbursements are limited to cases of improper deflection under s. 2.1(7) of Regulation 283. The ruling aligns with Allstate Insurance Company of Canada v. Motor Vehicle Accident Claims Fund, reinforcing that the regulatory scheme prioritizes prompt benefit distribution and aims to prevent prolonged and costly arbitration disputes.

⚖️ Canadian Case Watch

 🚗Elkin Injury Law v. Smith, 2025 ONSC 1384

The court ruled on competing motions in a legal fees dispute between EIL and a former client. The case concerns unpaid legal fees for services EIL provided regarding an accident benefits claim from 2015 to 2024.

What Matters in This Case

Obligations in Civil Procedure –

In the recent ruling, the court underscored the imperative nature of adherence to procedural protocols by all parties involved in the litigation process. It was clearly articulated that compliance with requirements, including submitting a comprehensive affidavit of documents and participating in discovery proceedings, is non-negotiable. Importantly, the court noted that a failure by one party to fulfill these obligations does not absolve the other party of their responsibility to comply with procedural mandates. Such a stance reinforces the principle that the integrity of the judicial process relies on the diligence and accountability of all parties engaged in litigation.

Fairness in Legal Fees –

The case at hand brings forth critical inquiries regarding the reasonableness of legal fees, underscoring the court's inherent supervisory authority over such fees, which extends beyond the confines of formal assessment proceedings. It is essential to recognize that the determination of fee reasonableness is not merely a matter of contractual agreement but is subject to the oversight of the judiciary to ensure fairness and equity in billing practices. This consideration reflects the court's commitment to upholding the integrity of the legal profession and protecting the interests of clients engaged in litigation. Thus, a thorough examination of the circumstances surrounding the fees in question is imperative to ascertain compliance with established standards of reasonableness.

Disclosure and Privilege –

In the matter at hand, the court has rendered a decision requiring Elkin Injury Law (EIL) to furnish its accident benefits file to the requesting party. Notably, the court has concurrently upheld the assertion of privilege by EIL concerning documents that pertain to internal legal work. This delineation affirms the protection of communications and materials prepared in anticipation of litigation while ensuring that relevant accident benefit documents remain accessible for review. Such a ruling underscores the balance between the obligation to disclose pertinent evidence and the preservation of attorney-client confidentiality and legal strategy.

Solicitor-Client Relationship Issues –

In the matter at hand, the dispute emerged subsequent to the defendant's transition to new legal representation. This situation underscores the complexities inherent in fee disputes that often arise when clients navigate the process of changing law firms. The shifting of counsel complicates the continuity of legal strategies and raises pertinent questions regarding the allocation of fees incurred prior to and following the representation change. Such circumstances necessitate a careful examination of the contractual obligations between the client and the original counsel and the ethical considerations that govern the profession. Therefore, it is imperative to address these issues to ensure fair resolution and maintain the legal process's integrity.

Key Takeaways

Courts can scrutinize legal fees –

Courts possess the authority to evaluate and scrutinize the legality and reasonableness of legal fees charged in a case. Even in the absence of a formal fee assessment process, judges can still examine the fairness of these fees during a lawsuit. This ensures that clients are not subjected to excessive or unjustified charges, promoting transparency and accountability within the legal system.

Both parties must comply with procedural rules –

In the matter before the court, it is imperative to note that the defendant’s failure to submit a requisite affidavit of documents does not relieve the plaintiff of his or her responsibility to provide a comprehensive and complete affidavit. The obligation to furnish a full disclosure of documents remains a fundamental principle, compliant with procedural rules, as it ensures the integrity of the discovery process and promotes transparency between the parties. Thus, the plaintiff must fulfill this duty notwithstanding the shortcomings of the defendant’s submissions.

Some legal work may be privileged –

In the context of discovery proceedings, it is essential to understand the balance between a party's entitlement to relevant documents and the protections afforded by legal privilege. Having a vested interest in accessing EIL’s accident benefits file, the defendant is entitled to those documents as they are pertinent to the case at hand. However, it is equally important to recognize that certain internal communications and materials maintained by EIL may be protected under solicitor-client privilege or other applicable privileges.

Specifically, internal notes, emails, and billing records that reflect strategy, legal advice, or internal deliberations related to handling the accident benefits claim may be withheld from disclosure. The rationale is to safeguard the confidentiality of the legal process and ensure that open and honest communication between legal counsel and their clients is not compromised.

It is crucial for parties involved to adhere to the guidelines outlined in the applicable rules of civil procedure when determining the scope of discovery and the invocation of privilege. Thus, while the defendant has a right to relevant files, EIL is justified in asserting its privilege over materials that fall outside the realm of discoverable evidence.

Final order:

The court ordered Smith to submit the required documents within 14 days. Additionally, EIL must provide a revised affidavit within 30 days, ensuring that any privileged documents are listed separately. Smith is also required to attend discovery proceedings within 45 days. Given that neither party fully succeeded in their motions, the court decided not to award costs to either side.

🎙️ Interview Clip

 Future of Law AI, Lawsuits, and Legal Innovation

Alistair Vigier, CEO of Caseway :

Quote: “Will AI replace lawyers I think AI will definitely replace lawyers the way that lawyers are today at the nature of lawyers will evolve and I think you'll see lawyers is kind of like an AI whisper where they're trained highly in how to use AI AI is doing most of the work for them but they were the real experts that are kind of the managers overseeing the file and checking things before it goes out.”

Interpretation: The assertion posits that artificial intelligence (AI) is poised to fundamentally alter the landscape of the legal profession. Specifically, it indicates that AI will automate many routine functions, including document review and legal research. However, it is critical to understand that such advancements will not culminate in the wholesale replacement of legal practitioners.

Rather, the role of attorneys will undergo a significant transformation, positioning them as "AI whisperers." In this capacity, lawyers will cultivate expertise in harnessing AI technologies to augment their practice. The profession is expected to evolve, with attorneys transitioning from executing repetitive tasks to serving as expert managers. They will oversee outputs generated by AI systems, ensuring precision and reliability, while also engaging in vital decision-making processes that demand human judgment, ethical reasoning, and strategic foresight.

In this new paradigm, lawyers will remain indispensable despite AI managing substantial operational workloads. Their unique capabilities in navigating intricate legal frameworks, fostering client relationships, and delivering nuanced legal counsel will continue to hold value. This trend aligns with a broader perspective that views technology as a complementary force that enhances rather than supplants skilled professionals within the legal domain.

📩 Stay Smart, Stay Ahead

If you found this valuable, please forward it to a friend or colleague in PI law, legal ops, or insurance.

💬 Got a story tip, tool to test, or want to collaborate? Email me at [email protected]